<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2(2)</volume><submitter>Vasku V</submitter><pubmed_abstract>Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.</pubmed_abstract><journal>International journal of clinical and experimental pathology</journal><pagination>163-8</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2583633</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pharmacogenetic contribution of leptin gene polymorphism in cutaneous T-cell lymphoma.</pubmed_title><pmcid>PMC2583633</pmcid><pubmed_authors>Vasku A</pubmed_authors><pubmed_authors>Vasku V</pubmed_authors><pubmed_authors>Vasku JB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pharmacogenetic contribution of leptin gene polymorphism in cutaneous T-cell lymphoma.</name><description>Leptin has recently attracted more attention due to its specific effects in the pathogenesis of malignancies. The aim of this study was to investigate the possible association between variants of -2548 G/A polymorphism in leptin (LEP) gene and cutaneous T-cell lymphomas (CTCL), with respect to the treatment responsiveness. A sample of 91 patients with CTCL was compared to 198 control individuals. The CTCL men with AG and/or GG genotype were more likely to receive the topical steroids treatment (odds ratio 7.88, 95% confidential interval 1.51-41.04) when compared to AA patients. Our data supports the possible involvement of LEP-2548G/A polymorphism in CTCL treatment responsiveness and thus might provide important information for individual therapy tailoring.</description><dates><release>2009-01-01T00:00:00Z</release><publication>2009</publication><modification>2024-10-18T21:08:17.087Z</modification><creation>2019-03-27T00:19:22Z</creation></dates><accession>S-EPMC2583633</accession><cross_references><pubmed>19079651</pubmed></cross_references></HashMap>